Lindsay M Morton1, Graça M Dores, Rochelle E Curtis, Charles F Lynch, Marilyn Stovall, Per Hall, Ethel S Gilbert, David C Hodgson, Hans H Storm, Tom Børge Johannesen, Susan A Smith, Rita E Weathers, Michael Andersson, Sophie D Fossa, Michael Hauptmann, Eric J Holowaty, Heikki Joensuu, Magnus Kaijser, Ruth A Kleinerman, Frøydis Langmark, Eero Pukkala, Leila Vaalavirta, Alexandra W van den Belt-Dusebout, Joseph F Fraumeni, Lois B Travis, Berthe M Aleman, Flora E van Leeuwen. 1. Lindsay M. Morton, Graça M. Dores, Rochelle E. Curtis, Ethel S. Gilbert, Ruth A. Kleinerman, and Joseph F. Fraumeni Jr, National Cancer Institute, Bethesda, MD; Graça M. Dores, Department of Veterans Affairs Medical Center, Oklahoma City, OK; Charles F. Lynch, University of Iowa, Iowa City, IA; Marilyn Stovall, Susan A. Smith, and Rita E. Weathers, University of Texas MD Anderson Cancer Center, Houston, TX; Per Hall and Magnus Kaijser, Karolinska Institute, Stockholm, Sweden; David C. Hodgson and Eric J. Holowaty, University of Toronto, Toronto, Ontario, Canada; Hans H. Storm, Danish Cancer Society; Michael Andersson, Copenhagen University Hospital, Copenhagen, Denmark; Tom Børge Johannesen and Frøydis Langmark, Cancer Registry of Norway; Sophie D. Fossa, Oslo University Hospital and University of Oslo, Oslo, Norway; Michael Hauptmann, Alexandra W. Van den Belt-Dusebout, Berthe M. Aleman, and Flora E. van Leeuwen, Netherlands Cancer Institute, Amsterdam, the Netherlands; Heikki Joensuu and Leila Vaalavirta, Helsinki University Central Hospital; Eero Pukkala, Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland; Lois B. Travis, University of Rochester Medical Center, Rochester, NY.
Abstract
PURPOSE: Treatment-related stomach cancer is an important cause of morbidity and mortality among the growing number of Hodgkin lymphoma (HL) survivors, but risks associated with specific HL treatments are unclear. PATIENTS AND METHODS: We conducted an international case-control study of stomach cancer nested in a cohort of 19,882 HL survivors diagnosed from 1953 to 2003, including 89 cases and 190 matched controls. For each patient, we quantified cumulative doses of specific alkylating agents (AAs) and reconstructed radiation dose to the stomach tumor location. RESULTS: Stomach cancer risk increased with increasing radiation dose to the stomach (Ptrend < .001) and with increasing number of AA-containing chemotherapy cycles (Ptrend = .02). Patients who received both radiation to the stomach ≥ 25 Gy and high-dose procarbazine (≥ 5,600 mg/m(2)) had strikingly elevated stomach cancer risk (25 cases, two controls; odds ratio [OR], 77.5; 95% CI, 14.7 to 1452) compared with those who received radiation < 25 Gy and procarbazine < 5,600 mg/m(2) (Pinteraction < .001). Risk was also elevated (OR, 2.8; 95% CI, 1.3 to 6.4) among patients who received radiation to the stomach ≥ 25 Gy but procarbazine < 5,600 mg/m(2); however, no procarbazine-related risk was evident with radiation < 25 Gy. Treatment with dacarbazine also increased stomach cancer risk (12 cases, nine controls; OR, 8.8; 95% CI, 2.1 to 46.6), after adjustment for radiation and procarbazine doses. CONCLUSION: Patients with HL who received subdiaphragmatic radiotherapy had dose-dependent increased risk of stomach cancer, with marked risks for patients who also received chemotherapy containing high-dose procarbazine. For current patients, risks and benefits of exposure to both procarbazine and subdiaphragmatic radiotherapy should be weighed carefully. For patients treated previously, GI symptoms should be evaluated promptly.
PURPOSE: Treatment-related stomach cancer is an important cause of morbidity and mortality among the growing number of Hodgkin lymphoma (HL) survivors, but risks associated with specific HL treatments are unclear. PATIENTS AND METHODS: We conducted an international case-control study of stomach cancer nested in a cohort of 19,882 HL survivors diagnosed from 1953 to 2003, including 89 cases and 190 matched controls. For each patient, we quantified cumulative doses of specific alkylating agents (AAs) and reconstructed radiation dose to the stomach tumor location. RESULTS:Stomach cancer risk increased with increasing radiation dose to the stomach (Ptrend < .001) and with increasing number of AA-containing chemotherapy cycles (Ptrend = .02). Patients who received both radiation to the stomach ≥ 25 Gy and high-dose procarbazine (≥ 5,600 mg/m(2)) had strikingly elevated stomach cancer risk (25 cases, two controls; odds ratio [OR], 77.5; 95% CI, 14.7 to 1452) compared with those who received radiation < 25 Gy and procarbazine < 5,600 mg/m(2) (Pinteraction < .001). Risk was also elevated (OR, 2.8; 95% CI, 1.3 to 6.4) among patients who received radiation to the stomach ≥ 25 Gy but procarbazine < 5,600 mg/m(2); however, no procarbazine-related risk was evident with radiation < 25 Gy. Treatment with dacarbazine also increased stomach cancer risk (12 cases, nine controls; OR, 8.8; 95% CI, 2.1 to 46.6), after adjustment for radiation and procarbazine doses. CONCLUSION:Patients with HL who received subdiaphragmatic radiotherapy had dose-dependent increased risk of stomach cancer, with marked risks for patients who also received chemotherapy containing high-dose procarbazine. For current patients, risks and benefits of exposure to both procarbazine and subdiaphragmatic radiotherapy should be weighed carefully. For patients treated previously, GI symptoms should be evaluated promptly.
Authors: David C Hodgson; Ethel S Gilbert; Graça M Dores; Sara J Schonfeld; Charles F Lynch; Hans Storm; Per Hall; Froydis Langmark; Eero Pukkala; Michael Andersson; Magnus Kaijser; Heikki Joensuu; Sophie D Fosså; Lois B Travis Journal: J Clin Oncol Date: 2007-03-19 Impact factor: 44.544
Authors: J D Boice; G Engholm; R A Kleinerman; M Blettner; M Stovall; H Lisco; W C Moloney; D F Austin; A Bosch; D L Cookfair; E T Krementz; H B Latourette; J A Merrill; L J Peters; M D Schulz; H H Storm; E Bjorkholm; F Pettersson; C M Janine Bell; M P Coleman; P Fraser; F E Neal; P Prior; N W Choi; T G Hislop; M Koch; N Kreiger; D Robb; D Robson; D H Thomson; H Lochmuller; D von Fournier; R Frischkorn; K E Kjørstad; A Rimpela; M H Pejovic; V P Kirn; H Stankusova; F Berrino; K Sigurdsson; G B Hutchison; B MacMahon Journal: Radiat Res Date: 1988-10 Impact factor: 2.841
Authors: Ann C Mertens; Qi Liu; Joseph P Neglia; Karen Wasilewski; Wendy Leisenring; Gregory T Armstrong; Leslie L Robison; Yutaka Yasui Journal: J Natl Cancer Inst Date: 2008-09-23 Impact factor: 11.816
Authors: Lindsay M Morton; Ethel S Gilbert; Marilyn Stovall; Flora E van Leeuwen; Graça M Dores; Charles F Lynch; Per Hall; Susan A Smith; Rita E Weathers; Hans H Storm; David C Hodgson; Ruth A Kleinerman; Heikki Joensuu; Tom Børge Johannesen; Michael Andersson; Eric J Holowaty; Magnus Kaijser; Eero Pukkala; Leila Vaalavirta; Sophie D Fossa; Frøydis Langmark; Lois B Travis; Stephanie Lamart; Steven L Simon; Joseph F Fraumeni; Berthe M Aleman; Rochelle E Curtis Journal: Haematologica Date: 2014-10 Impact factor: 9.941
Authors: Sean P Dineen; Christina L Roland; Rachel Feig; Caitlin May; Shouhao Zhou; Elizabeth Demicco; Ghadah Al Sannaa; Davis Ingram; Wei-Lein Wang; Vinod Ravi; Ashleigh Guadagnolo; Dina Lev; Raphael E Pollock; Kelly Hunt; Janice Cormier; Alex Lazar; Barry Feig; Keila E Torres Journal: Ann Surg Oncol Date: 2015-03-06 Impact factor: 5.344
Authors: Matthew B Yurgelun; Jason L Hornick; Victoriana K Curry; Chinedu I Ukaegbu; Emily K Brown; Elaine Hiller; Anu Chittenden; Joel E Goldberg; Sapna Syngal Journal: Clin Gastroenterol Hepatol Date: 2013-12-19 Impact factor: 11.382